Physicians' Academy for Cardiovascular Education

Treatment with PCSK9 inhibitor can lower frequency of lipoprotein apheresis in FH patients

ESC 2016 - Rome

News - Sep. 1, 2016

ESCAPE - Effect of alirocumab on the frequency of lipoprotein apheresis: a randomised Phase III trial

Presented at the ESC congress 2016 by: Patrick Moriarty (Kansas City, KA, USA)
 

Background

Untreated familial hypercholesterolaemia (heFH) is associated with severely elevated LDL-c levels and a high risk of premature CHD. Despite LDL-c-lowering drug therapy, many patients with FH do not reach their target LDL-c levels. Lipoprotein apheresis (LA) effectively removes LDL-c by 50-75% and is considered as lipid-lowering option if LDL-c levels are not adequately lowered with maximally tolerated drug therapy. The procedure is time-consuming (up to 4 hours, performed weekly or biweekly) and costly, and can only be performed in specialised clinics.
The ODYSSEY-ESCAPE was designed to study whether adding the fully human monoclonal antibody directed at PCSK9 alirocumab to LA therapy could reduce or eliminate apheresis therapy. Male and female HeFH patients >18 years old undergoing weekly or biweekly LA were randomised to treatment with alirocumab 150 mg Q2W s.c. or placebo Q2W s.c. for 18 weeks (double-blind). During the first 6 weeks of this treatment period, frequency of LA was fixed, and in the last 12 weeks LA was only performed if LDL-c was <30% lower than at baseline LDL (pre-apheresis). During an 8-week follow-up period all patients received alirocumab 150 mg Q2W s.c.
Patients were on stable background therapy and had undergone consistent LA weekly for at least 4 weeks or biweekly for at least 8 weeks. The primary efficacy endpoint was frequency of apheresis treatment over 12 weeks, normalised according to the number of planned sessions.
 

Main results

  • 63.4% of patients on alirocumab did not undergo any apheresis treatments between week 7 and week 18. In placebo-treated patients, no one skipped all treatments in this period.
  • 17.1% of patients on alirocumab had a standard apheresis rate between 0 and 0.25.
  • 12.2% of patients on alirocumab and 14.3% on placebo had a standardised apheresis rate between 0.25 and 0.5.
  • 2.4% of patients on alirocumab and 23.8% on placebo had a standardised apheresis rate between 0.5 and 0.75.
  • 2.4% of patients on alirocumab and 33.3% on placebo had a standardised apheresis rate between 0.75 and 1.
  • 2.4% of patients on alirocumab and 28.6% on placebo had a standardised apheresis rate of 1.
  • Least-square mean of time-averaged percentage change from baseline was -53.7 (SE: 2.3) with alirocumab and 1.6 (SE: 3.1) with placebo at week 6 (P<0.0001 for difference) and -42.5 (SE: 4.7) and 3.9 (SE: 6.3) respectively at week 18.
  • Any treatment-emergent adverse events (AEs) were seen in 31 of 41 patients on alirocumab (75.6%) and in 16 of 21 on placebo (76.2%). Serious AEs were seen in 4 patients on alirocumab (9.8%) and in 2 on placebo (9.5%).
 

Conclusion

In ODYSSEY ESCAPE, alirocumab significantly reduced the frequency of lipoprotein apheresis in patients with HeFH who were not achieving recommended LDL-C levels without this treatment. Lipoprotein apheresis was discontinued in 63.4% of patients receiving alirocumab who were
previously undergoing regular apheresis. 92.7% of patients on alirocumab received at most half of their usual LA treatments.

Our reporting is based on the information provided during the ESC congress

Share this page with your colleagues and friends: